Saturday, March 15, 2025 | 02:01 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Daiichi Sankyo shuts down Indian R&D unit

The unit mainly conducted drug discovery research targeting infectious diseases & inflammation

Daiichi Sankyo’s R&D unit in India
Premium

Daiichi Sankyo’s R&D unit in India

BS B2B Bureau New Delhi
Japanese pharmaceutical company Daiichi Sankyo Company Limited has decided to close its Gurgaon (Haryana) based research subsidiary, Daiichi Sankyo India Pharma Private Limited (DSIN), to increase its R&D productivity.

Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline.

DSIN presently employs approximately 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation. Following its closure, the DSIN R&D pipeline - including research themes selected by the Global Health Innovative Technology Fund (GHIT Fund) - will be transferred to Daiichi Sankyo’s

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in